U.S. Lawmakers Seek to Bar Chinese Biotech Companies over Concerns about Competition and National Security
Lawmakers in the United States are raising concerns about China’s dominance in the biotechnology industry and the potential risks it poses to American national security and commercial interests. In light of these fears, bills have been introduced in both the House and Senate to prevent “foreign adversary biotech companies of concern” from conducting business with federally funded medical providers.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
